Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

"Korro's unique RNA-editing platform has the potential to bring transformative genetic medicines to patients with rare and highly prevalent diseases and provide hope where there is significant unmet need," said Dr. Vincent. "I look forward to supporting the mission at Korro and joining its talented management team." CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines base ...